PURPOSE OF REVIEW: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are antihyperglycemic drugs that act by inhibiting renal sodium-glucose cotransport. Here we present new insights into 'off target', or indirect, effects of SGLT2 inhibitors. RECENT FINDINGS: SGLT2 inhibition causes an acute increase in urinary glucose excretion. In addition to lowering blood glucose, there are several other effects that contribute to the overall beneficial renal and cardiovascular effects. Reabsorption of about 66% of sodium is accomplished in the proximal tubule and dependent on the sodium-hydrogen exchanger isoform 3 (NHE3). SGLT2 colocalizes with NHE3, and high glucose levels reduce NHE3 activity. The proximal tubule is also responsible for the majority of phosphate (Pi) reabsorption. SGLT2 inhibition is associated with increases in plasma Pi, fibroblast growth factor 23 and parathyroid hormone levels in nondiabetics and type 2 diabetes mellitus. Studies in humans identified a urate-lowering effect by SGLT2 inhibition which is possibly mediated by urate transporter 1 (URAT1) and/or glucose transporter member 9 in the proximal tubule. Of note, magnesium levels were also found to increase under SGLT2 inhibition, an effect that was preserved in nondiabetic patients with hypomagnesemia. SUMMARY: Cardiorenal effects of SGLT2 inhibition might involve, in addition to direct effects on glucose homeostasis, effects on NHE3, phosphate, urate, and magnesium homeostasis.
PURPOSE OF REVIEW: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are antihyperglycemic drugs that act by inhibiting renal sodium-glucose cotransport. Here we present new insights into 'off target', or indirect, effects of SGLT2 inhibitors. RECENT FINDINGS: SGLT2 inhibition causes an acute increase in urinary glucose excretion. In addition to lowering blood glucose, there are several other effects that contribute to the overall beneficial renal and cardiovascular effects. Reabsorption of about 66% of sodium is accomplished in the proximal tubule and dependent on the sodium-hydrogen exchanger isoform 3 (NHE3). SGLT2 colocalizes with NHE3, and high glucose levels reduce NHE3 activity. The proximal tubule is also responsible for the majority of phosphate (Pi) reabsorption. SGLT2 inhibition is associated with increases in plasma Pi, fibroblast growth factor 23 and parathyroid hormone levels in nondiabetics and type 2 diabetes mellitus. Studies in humans identified a urate-lowering effect by SGLT2 inhibition which is possibly mediated by urate transporter 1 (URAT1) and/or glucose transporter member 9 in the proximal tubule. Of note, magnesium levels were also found to increase under SGLT2 inhibition, an effect that was preserved in nondiabetic patients with hypomagnesemia. SUMMARY: Cardiorenal effects of SGLT2 inhibition might involve, in addition to direct effects on glucose homeostasis, effects on NHE3, phosphate, urate, and magnesium homeostasis.
Authors: Thomas Voets; Bernd Nilius; Susan Hoefs; Annemiete W C M van der Kemp; Guy Droogmans; Rene J M Bindels; Joost G J Hoenderop Journal: J Biol Chem Date: 2003-10-23 Impact factor: 5.157
Authors: Xiaoxin X Wang; Jonathan Levi; Yuhuan Luo; Komuraiah Myakala; Michal Herman-Edelstein; Liru Qiu; Dong Wang; Yingqiong Peng; Almut Grenz; Scott Lucia; Evgenia Dobrinskikh; Vivette D D'Agati; Hermann Koepsell; Jeffrey B Kopp; Avi Z Rosenberg; Moshe Levi Journal: J Biol Chem Date: 2017-02-14 Impact factor: 5.157
Authors: Volker Vallon; Michael Rose; Maria Gerasimova; Joseph Satriano; Kenneth A Platt; Hermann Koepsell; Robyn Cunard; Kumar Sharma; Scott C Thomson; Timo Rieg Journal: Am J Physiol Renal Physiol Date: 2012-11-14
Authors: Kathryn M Thrailkill; R Clay Bunn; Sasidhar Uppuganti; Philip Ray; Kate Garrett; Iuliana Popescu; Jacquelyn S Pennings; John L Fowlkes; Jeffry S Nyman Journal: Bone Date: 2020-01-25 Impact factor: 4.398
Authors: Valentin Gorboulev; Annette Schürmann; Volker Vallon; Helmut Kipp; Alexander Jaschke; Dirk Klessen; Alexandra Friedrich; Stephan Scherneck; Timo Rieg; Robyn Cunard; Maike Veyhl-Wichmann; Aruna Srinivasan; Daniela Balen; Davorka Breljak; Rexhep Rexhepaj; Helen E Parker; Fiona M Gribble; Frank Reimann; Florian Lang; Stefan Wiese; Ivan Sabolic; Michael Sendtner; Hermann Koepsell Journal: Diabetes Date: 2011-11-28 Impact factor: 9.461
Authors: Olha Kravtsova; Ruslan Bohovyk; Vladislav Levchenko; Oleg Palygin; Christine A Klemens; Timo Rieg; Alexander Staruschenko Journal: Am J Physiol Renal Physiol Date: 2022-04-25